EDI-200

Summary

EDI-200 (also called ER004, anti‑EDAR agonist antibody) is an investigational monoclonal antibody fragment designed to replace the missing ectodysplasin‑A1 (EDA1) protein in fetuses with X‑linked hypohidrotic ectodermal dysplasia (XLHED). By binding the EDA1 receptor (EDAR) during prenatal development, it aims to restore normal signaling for skin, hair, teeth, and sweat‑gland formation. The compound is being studied in a Phase 2 open‑label trial that administers the drug intra‑amniotically to male fetuses carrying pathogenic EDA mutations.

Mechanism of Action

EDI‑200 is a high‑affinity anti‑EDAR agonist antibody that mimics the natural ligand ectodysplasin‑A1. When introduced into the amniotic fluid, it binds the EDAR receptor on ectodermal progenitor cells, triggering the EDA/NF‑κB signaling cascade. This cascade drives transcription of genes required for the differentiation and morphogenesis of sweat glands, teeth, hair follicles, and mucosal glands, thereby attempting to correct the developmental deficit caused by EDA loss‑of‑function mutations.

What the Research Shows

Preclinical work demonstrated that EDI‑200 can activate EDAR signaling and promote ectodermal organ development in animal models. Subsequent named‑patient use cases reported that intra‑amniotic administration to fetuses with XLHED in the late second or third trimester was associated with measurable improvements in sweat‑gland function and tooth formation. To systematically evaluate these observations, the EDELIFE Phase 2 trial was launched; it is a prospective, open‑label, genotype‑matched, multicentre study that will administer EDI‑200 intra‑amniotically to male subjects with confirmed XLHED. The protocol outlines efficacy and safety endpoints, but efficacy data are not yet available.

Reported Benefits

If effective, EDI‑200 could provide the first disease‑modifying therapy for XLHED by restoring the developmental signaling that is absent in affected males. Potential clinical benefits include the formation of functional sweat glands (reducing hyperthermia risk), improved tooth development, and healthier skin appendages, which together may lower morbidity from respiratory infections and heat‑related complications.

Limitations of the Evidence

Evidence to date is limited to animal studies and a small number of compassionate‑use cases; no controlled efficacy data have been published. The ongoing trial has not reported outcomes, so the magnitude and durability of any benefit remain unknown. The therapy is restricted to male fetuses with confirmed EDA null mutations, and the requirement for intra‑amniotic delivery poses logistical and ethical challenges. Long‑term safety and immunogenicity have not been established.

Safety Considerations

The abstract does not detail adverse events, but intra‑amniotic injection carries inherent risks such as infection, preterm labor, fetal injury, and maternal complications. As a recombinant antibody fragment, EDI‑200 could provoke immune responses in the fetus or mother, potentially leading to neutralising antibodies or hypersensitivity. Ongoing monitoring in the Phase 2 trial will assess these safety parameters, but clinicians should consider the unknown risk profile when evaluating prenatal use.

How It Is Administered

EDI‑200 is formulated for injection into the amniotic cavity during the late second or third trimester of pregnancy, allowing direct exposure of the fetus to the protein. Intravenous administration is also listed as a possible route, though the current trial focuses on intra‑amniotic delivery. Dosing regimens and schedules are defined within the trial protocol and are not publicly disclosed.

Routes of Administration

Goals & Uses

• Treatment of XLHEDRare Genetic DiseaseModerate
• Restoration of sweat gland developmentRare Disease / Ectodermal DysplasiaModerate
• Improvement of dental and hair developmentRare Disease / Ectodermal DysplasiaLow
• Prevention of hyperthermia riskSymptom PreventionModerate

Contraindications

• Known hypersensitivity to EDI-200 or its componentsAllergy / ImmunologyHigh
• Infections not under adequate treatmentInfectious DiseaseModerate

Adverse Effects

• Transient laboratory abnormalitiesLaboratoryUncommon
• FeverSystemicUncommonElevated body temperature
• Potential immunogenicity (ADA formation)ImmunologicUnknown
• Infusion-related reactionsHypersensitivityUncommon

Drug Interactions

• ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk

Population Constraints

• Pregnant women (fetal administration)PregnancyRelative
• Patients with active infectionsInfectious DiseaseRelative
• Pediatric neonatesAgeRelative

Regulatory Status

• European UnionInvestigationalOrphan Drug Designation granted by EMA for XLHED; not yet approved
• United StatesInvestigationalOrphan Drug Designation and Breakthrough Therapy Designation granted by FDA; not yet approved

Granted Orphan Drug Designation by the FDA and EMA for XLHED. Received Breakthrough Therapy Designation from the FDA. Not yet approved for marketing. Developed by Edimer Pharmaceuticals and later associated with Syndax/other sponsors.

Evidence & Sources

• Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia
  Journal ArticleModerateSchneider H, et al.2023-01-01T00:00:00.000000Z

Frequently Asked Questions